Get notified when RGEN files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- 66% of Biolife’s Total Revenue Comes From Its Top Ten (10) Customers (new) — BioLife's revenue is highly concentrated among its top ten customers, posing a risk if any of these customers reduce orders or switch suppliers.
- Dual-class / Super-voting Structure (new) — Prospectus discloses a dual-class or super-voting capital structure that concentrates voting power; public holders may have limited control over director elections and other matters requiring a stockholder vote.
Repligen to acquire BioLife Solutions in stock-and-cash deal valued at $31.00 per BioLife share
Filed September 4, 2026 · ~1 min read
Key Changes
-
high
Each BioLife share converts into 0.1442 Repligen shares plus $11.25 cash, implying $31.00 per BioLife share based on Repligen's July 21, 2026 close.
The Offering verify on EDGAR → -
high
BioLife stockholders will own about 11.1% of the combined company; Repligen stockholders will own about 88.9%.
Risk Factors verify on EDGAR → -
medium
The merger is intended to qualify as a tax-free reorganization under Section 368(a) of the Internal Revenue Code.
Business view on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (FPS 10-K) is open in full — no account needed.
Partner
Trade RGEN commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 4, 2026 · How we verify